Coloplast playing it safe with new guidance due to inflation

The Danish medtech firm now risks failing to meet its long-term objectives, as revealed in the annual report for 2021/2022.

Photo: Stine Bidstrup/ERH

In the worst-case scenario, Coloplast now has an outlook to an operating (EBIT) margin in skewed financial year 2022/2023 that falls short of the company’s long-term expectations due to inflation on energy and commodity prices, in particular.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs